Request Demo

Last update 23 Jan 2025

Thiamine Hydrochloride

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryThiamine Hydrochlorid (also known as Vitamin B1), is a small molecule drug that acts as a vitamin B1 supplement. Approved in December 1952, and is typically administered orally or intravenously.

Drug Type

Small molecule drug

Synonyms

Thiamine Chloride Hydrochloride, Thiamine chloride hydrochloride (JP17), Thiamine hydrochloride (USP)

+ [26]

Target-

Mechanism

Vitamin B1 supplements

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Thiamine Deficiency

Inactive Indication-

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Biological Therapies

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Dec 1952),

Thiamine Deficiency

Regulation-

Structure/Sequence

Molecular FormulaC12H18Cl2N4OS

InChIKeyDPJRMOMPQZCRJU-UHFFFAOYSA-M

CAS Registry67-03-8

View All Structures (2)

192

Clinical Trials associated with Thiamine Hydrochloride

IRCT20190224042815N1

/ SuspendedPhase 2/3IIT

Evaluating the preventive effect of vitamin B1 on Delirium in critically ill patients

Start Date18 May 2640

Sponsor / Collaborator

Tehran University of Medical Sciences

NCT05083546

/ Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

CTRI/2024/11/076607

/ Not yet recruitingPhase 3IIT

Comparative Assessment of Efficacy of Vitamin B12 spray versus Benzydamine Hydrochloride spray in Prevention and Management of Radiation Mucositis-A Randomized Clinical Trial - NIL

Start Date28 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Thiamine Hydrochloride

100 Translational Medicine associated with Thiamine Hydrochloride

100 Patents (Medical) associated with Thiamine Hydrochloride

9,856

Literatures (Medical) associated with Thiamine Hydrochloride

01 Feb 2025·Nutrition Reviews

Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: a systematic review of randomized controlled trials

Review

Author: Ferreira, Amy ; Kellow, Nicole J ; Iacovou, Marina ; Robinson, Jazz

AbstractContextPremenstrual syndrome (PMS) affects approximately 48% of women of reproductive age worldwide. It can lead to functional impairment, lower quality of life, and decreased work productivity. Despite the availability of medical treatment options, women are seeking alternative interventions because of concerns of harmful side effects and limited evidence of efficacy associated with pharmacological treatments. To date, high-quality research investigating the effects of dietary and nutrient intervention on PMS is limited.ObjectiveThis systematic review investigated the effect of nutritional interventions on the psychological symptoms of PMS.Data SourcesFive electronic databases were searched for randomized controlled trials (RCTs) published in English from inception to October 2022. Trials eligible for inclusion were nutritional intervention studies involving women of reproductive age that measured PMS-associated psychological outcomes.Data ExtractionArticles were selected using prespecified inclusion criteria. Data screening and extraction and risk-of-bias assessments were conducted by 3 independent reviewers using article screening software and the Cochrane Risk of Bias 2 tool.Data AnalysisThirty-two articles reporting on 31 RCTs involving 3254 participants, ranging in age from 15 to 50 years were included and narratively reviewed. Only 1 of the included studies had a low risk of bias. Treatment with vitamin B6, calcium, and zinc consistently had significant positive effects on the psychological symptoms of PMS. There was insufficient evidence to support the effects of vitamin B1, vitamin D, whole-grain carbohydrates, soy isoflavones, dietary fatty acids, magnesium, multivitamin supplementation, or PMS-specific diets.ConclusionsThere is some evidence to support the use of nutritional interventions for improving psychological symptoms of PMS. However, more research using consistent protocols, procedures to minimize risk of bias, intention-to-treat analysis, and clearer reporting is required to provide conclusive nutritional recommendations for improving PMS-related psychological outcomes.PROSPERO registration noCRD42022369999.

01 Feb 2025·Clinical Nutrition ESPEN

Dietary supplementation use for outpatient treatment in children: A cross-sectional study

Article

Author: Le Thi, Tuong Vi ; Nguyen, Tien Minh ; Pham, Em Canh ; Le, Thanh Chi ; Nguyen, Nam Tran

OBJECTIVEDietary supplements (DSs) are commonly used supplements among children to support disease treatment, however, overuse and inappropriate prescription of outpatient DS can negatively affect health and treatment costs. This study aimed to evaluate DS use in outpatient treatment in children.METHODSThe present study used a cross-sectional descriptive retrospective method based on data from 188,579 outpatient prescriptions of children for 1 year.RESULTSDSs were commonly prescribed in pediatric patients ≤5 years old (63.48 %) with diagnosing respiratory, infectious, and gastrointestinal diseases (>50 %). DS costs account for a high proportion (24.86 %) of total outpatient prescription costs. In addition, pediatric prescriptions containing one DS product (88.16 %) showed a higher rate than prescriptions containing two DS products (11.84 %) with the main ingredients being vitamin D₃ (80.55 %), vitamin B₆ (63.01 %), vitamin B₁ (60.22 %), and vitamin B₂ (59.04 %), and calcium (51.0 %). The majority of DS products contained multivitamins (69.52 %) with DS containing ≥5 vitamins of 59.04 % and DS containing 2-4 vitamins of 10.48 %. Besides, non-compliance with DS prescribing guidelines for age (21.38 %), dose (14.13 %), and both age and dose (5.54 %) was found primarily in highly prescribed DSs (vitamin-amino acid-mineral ingredients), pediatric patients <2 years old, prescriptions containing one DS product or multivitamins, and respiratory disease group (J and R04-09 ICD). The univariate and multivariate regression analyses showed that vitamin-mineral products and groups <2 years old were significantly associated with guideline-adherent DS prescribing for age and/or dose. Meanwhile, foreign DSs and vitamin-mineral ingredients of prescription showed significant associations with guideline-adherent DS prescribing for age or dose.CONCLUSIONInstructions for DS use regarding recommended age and maximum dosage may not be carefully considered by doctors due to belonging to an over-the-counter medicine group. Therefore, there is a strong need for a national public policy to prevent and control overprescribing and inappropriate prescribing of DS.

01 Feb 2025·Legal Medicine

Comprehensive study of various vitamin concentrations in the human postmortem blood with an autopsy case report of beriberi

Article

Author: Kanetake, Jun ; Hosoya, Tadashi ; Harada, Kazuki

Using human cardiac blood from forensic autopsy cases, comprehensive measurements of albumin, vitamins A, B1, B6, B12, C, D, folate, and PIVKA-Ⅱ were performed. Of 128 cases, 83 were male, with an average age of 61.8 years and average postmortem interval of 44 h. The average concentrations of vitamins were 29.8 μg/dL for vitamin A, 32.2 μg/dL for vitamin B1, 278 ng/mL for vitamin B6 (pyridoxamine), 152 ng/mL for vitamin B6 (pyridoxal), 57.2 ng/mL for vitamin B6 (pyridoxal), 17.9 ng/mL for folate, 1188 pg/mL for vitamin B12, 23.5 μg/mL for vitamin C, 15.0 ng/mL for vitamin D, and 1.03 μg/mL for PIVKA-Ⅱ. An autopsy case of a Japanese middle-aged male with beriberi was also presented, where severe edema and effusion of the cavity and a high NT-proBNP serum value were observed; however, cardiac pathology showed no specific abnormal features. In the present case, the blood vitamin B1 concentration was within the standard clinical range. This study revealed that bloodborne water-soluble vitamin levels shows higher to clinical standard value at postmortem, whereas fat-soluble vitamin levels may stay in the standard range or lower. Our findings suggest that postmortem water-soluble vitamin concentrations within the clinical standard may reflect low antemortem vitamin concentrations.

News (Medical) associated with Thiamine Hydrochloride

23 Sep 2024

·www.prnewswire.com

A PILL FOR ALZHEIMER'S DISEASE? CLINICAL TRIALS ON A NEW APPROACH TO TREATING ALZHEIMER'S STARTS AT 50 MEDICAL CENTERS ACROSS THE COUNTRY

NIH-funded trial will evaluate the effects of a synthetic version of vitamin B1 on cognitive function that was developed by Burke Institute for people with early Alzheimer's disease For more information about the trial and to find a study site, visit benfoteam.org WHITE PLAINS, N.Y., Sept. 23, 2024 /PRNewswire/ -- A completely different approach to stopping the progression of Alzheimer's disease pioneered by a research institute based in Westchester County, NY is now being tested nationwide. The Burke Neurological Institute (BNI), an affiliation of Weill Cornell Medicine, in partnership with the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego and Columbia University Irving Medical Center, have launched a national clinical trial to investigate the therapeutic potential of a BNI and Weill Cornell Medicine-developed form of benfotiamine, a synthetic version of vitamin B1 (thiamine), as a treatment for mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The BenfoTeam trial (The Phase 2A-2B study) taking place at 50 sites across the U.S. will evaluate the effects of benfotiamine on cognitive function and whether high doses benefit people 50-89 with mild AD and MCI. The trial is funded by the National Institute on Aging (NIA), a part of the National Institutes of Health (NIH). Benfotiamine is a synthetic drug which can increase blood thiamine up to 100 times the normal level. These levels of blood thiamine cannot be achieved by taking thiamine alone. The brain tissue in people with AD shows a thiamine deficiency, even with a sufficient supply of thiamine in a person's blood. The trial is investigating whether the delivery of thiamine via drug will increase the amount of thiamine getting to the brain and slow cognitive decline in people with early AD. Currently, 5.8 million Americans are living with AD with this number projected to rise to nearly 14 million people by 2050. "The approach of using benfotiamine in patients with mild Alzheimer's is very promising," said Rajiv Ratan, M.D., Ph.D., Executive Director at Burke Neurological Institute. "This clinical trial builds on years of hard work to address a disease that affects millions of patients " Howard Feldman, Director of the ADCS at UC San Diego said, "The launch of the BenfoTeam clinical trial represents a fresh approach with a potential treatment that is readily accessible, scientifically compelling, and cost-effective – that's a trifecta for a potential AD therapy in a Phase 2 trial – and benfotiamine has a strong safety profile." Gary E. Gibson, Ph.D., Professor of Neurosciences at BNI, has spent decades conducting studies to better understand Alzheimer's disease and how to develop new therapies to treat the disease. The BenfoTeam study builds on Gibson's scientific research conducted at Burke Neurological Institute – the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord. Gibson said many existing treatments or drugs in development only treat the symptoms of Alzheimer's disease such as amyloid plaques, but do not address the root cause of the disease. Benfotiamine has been shown to improve memory and diminish plaques, tangles, inflammation, and oxidative stress in animal models. In addition, unlike many of the other recently approved treatments for Alzheimer's disease, benfotiamine can be taken by mouth and does not require infusions. "In people with Alzheimer's disease, reductions in brain glucose utilization track closely with cognitive decline and we already know that thiamine deficiencies can cause dementia," said Gibson, who is also a Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. "We think people with mild cognitive impairment and Alzheimer's disease may not be getting enough thiamine delivered to the brain." Jose Luchsinger, M.D., MPH, Vice-Chair for Clinical and Epidemiologic Research at Columbia University and a BenfoTeam trial co-Principal Investigator said, "While Alzheimer's disease impacts all aging populations, it is not clear that recently approved Alzheimer's therapies benefit underrepresented racial and ethnic groups. The BenfoTeam trial is designed for all patient populations.'' Participation in the trial for each patient will last 18 months (plus screening) and enrollment is planned for 406 participants. For more information about the trial and to find a study site, visit benfoteam.org or call 877-807-1290 (toll free). This research will be supported by the NIH's National Institute on Aging (R01AG076634). This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH's National Institute on Aging. The ClinicalTrials.gov ID number for this study is: NCT06223360. About the BenfoTeam Partnership The BenfoTeam clinical research trial is funded by a grant from the National Institute on Aging (NIA) (R01AG076634). The clinical research trial is coordinated by the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego School of Medicine and is led by principal investigators from the Burke Neurological Institute and Weill Cornell Medicine, Columbia University Irving Medical Center, and UC San Diego. SOURCE Burke Neurological Institute WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

12 Sep 2024

·www.inotekcorp.com

Rhodo Eye Drops – Benefits, Usage, Side Effects, and Reviews

Rhodo eye drops are a popular ophthalmic solution that is used to provide relief from various eye conditions. These eye drops contain a unique formula that combines several key ingredients such as Rhododenol, hyaluronic acid, and vitamin B12. Rhododenol is a potent antioxidant that helps protect the eyes from oxidative stress and UV damage. Hyaluronic acid provides moisturizing and lubricating properties, which can help alleviate dryness and irritation in the eyes. Vitamin B12 is essential for maintaining healthy nerve function and may support overall eye health. These eye drops are designed to be gentle yet effective, making them suitable for individuals with sensitive eyes. They can be used to relieve symptoms of dryness, redness, itchiness, and fatigue, providing quick and soothing relief. Overall, Rhodo eye drops are a versatile and reliable solution for maintaining eye health and comfort on a daily basis. Using Rhodo eye drops can offer various benefits for your eye health and overall well-being. Here are some key advantages of incorporating Rhodo eye drops into your eye care routine: Relief from dry eyes: Rhodo eye drops contain lubricants that can help provide relief from dry eyes, which can be caused by factors such as digital eye strain, environmental conditions, or underlying health issues. Reduces eye irritation: The soothing properties of Rhodo eye drops can help reduce eye irritation, itchiness, and discomfort, providing a refreshing sensation to tired eyes. Improves eye hydration: By hydrating the eyes, Rhodo eye drops can help maintain the moisture balance in the eyes, preventing dryness and promoting overall eye health. Enhances clarity and vision: Regular use of Rhodo eye drops can help improve the clarity of your vision by reducing blurry vision and enhancing focus, especially during prolonged screen time or activities that strain the eyes. With these benefits, Rhodo eye drops can be a valuable addition to your eye care regimen, offering comfort, hydration, and support for optimal eye health. $35.66 $65.17 $29.00 $64.80 When using Rhodo eye drops, it is essential to follow the instructions provided on the packaging or by your healthcare provider. Here are some tips to help you use Rhodo eye drops effectively: Before using the eye drops, make sure to wash your hands thoroughly with soap and water. This will help prevent any contamination of the drops. Tilt your head back slightly and pull down your lower eyelid to create a small pocket. This will make it easier to administer the drops into your eye. Squeeze the bottle gently to release one drop into the pocket you created. Be careful not to touch your eye with the tip of the bottle to avoid contamination. After administering the drop, close your eyes gently for a few seconds to allow the medication to spread evenly over the surface of your eye. If your healthcare provider has instructed you to use more than one drop, wait at least five minutes before administering the next drop to allow the first one to be absorbed. Remember to store Rhodo eye drops in a cool, dry place, away from direct sunlight. Do not share your eye drops with others, as this can lead to infection or contamination. When considering eye drops for various eye conditions, it’s important to compare different products to choose the one that best suits your needs. Rhodo eye drops are a popular choice, but how do they compare to other similar products on the market? Let’s take a closer look at how Rhodo eye drops stack up against some competitors: While Visine is known for its redness relief properties, Zaditor targets allergies specifically. Rhodo eye drops, on the other hand, focus on providing relief for dry, red, and irritated eyes with the help of rhodiola extract and hyaluronic acid. The price point for Rhodo eye drops falls in between Visine and Zaditor, making it a budget-friendly option for those looking for holistic eye care. When it comes to user reviews, Rhodo eye drops have received positive feedback for their effectiveness in relieving eye discomfort without harsh chemicals. Users appreciate the natural ingredients and gentle approach to eye care provided by Rhodo eye drops. Considering the active ingredients, uses, and price point, Rhodo eye drops offer a unique alternative to other eye drops on the market, catering to individuals seeking natural eye care solutions. While Rhodo eye drops can provide relief for various eye conditions, it is important to be aware of potential side effects and take necessary precautions when using this product. Some users may experience mild burning or stinging sensation upon instillation of Rhodo eye drops. This discomfort is usually temporary and should subside quickly. In rare cases, individuals may develop allergic reactions to the ingredients in Rhodo eye drops. If you experience any signs of an allergic reaction such as itching, redness, swelling, or difficulty breathing, discontinue use immediately and seek medical attention. Long-term use of Rhodo eye drops may lead to rebound redness or dependence on the product. It is important to use Rhodo eye drops as directed and consult a healthcare professional if you have concerns about prolonged use. Do not touch the tip of the Rhodo eye drop container to avoid contamination. Avoid sharing your Rhodo eye drops with others to prevent the spread of infection. If you are pregnant or nursing , consult your healthcare provider before using Rhodo eye drops to ensure they are safe for you and your baby. It is essential to follow the instructions provided on the product packaging and consult a healthcare professional if you have any concerns about using Rhodo eye drops. By taking the necessary precautions and being aware of potential side effects, you can ensure a safe and effective experience with this eye drop solution. To provide a comprehensive overview of Rhodo eye drops, it’s essential to consider the experiences and feedback shared by actual users. Here are some testimonials and reviews from individuals who have used Rhodo eye drops: “I’ve been suffering from dry eyes for years, and I’ve tried numerous eye drops without much success. However, after using Rhodo eye drops for a few weeks, I noticed a significant improvement in the moisture level of my eyes. The drops are easy to use and have become a part of my daily routine.” “As someone who spends hours in front of a screen due to work, I often experience eye strain and discomfort. Rhodo eye drops have been a game-changer for me. They provide instant relief and soothing hydration to my eyes. I highly recommend them to anyone dealing with similar issues.” “I have sensitive eyes and have struggled to find eye drops that don’t irritate them further. Rhodo eye drops were recommended to me by a friend, and I’m so glad I tried them. Not only are they gentle on my eyes, but they also effectively alleviate redness and dryness. I won’t be switching to any other brand.” These testimonials highlight the positive experiences of individuals who have incorporated Rhodo eye drops into their eye care routines. The diverse range of users, from those with dry eyes to individuals dealing with eye strain, showcases the versatility and effectiveness of Rhodo eye drops in addressing various eye concerns. If you are interested in purchasing Rhodo eye drops, you can find them at various online and offline retailers. It is recommended to buy Rhodo eye drops from reputable sources to ensure the quality and authenticity of the product. Here are some of the popular online platforms where you can purchase Rhodo eye drops: Amazon Walgreens CVS Pharmacy The pricing of Rhodo eye drops may vary depending on the retailer and any ongoing promotions or discounts. It is advisable to compare prices across different platforms to find the best deal. On average, a bottle of Rhodo eye drops typically ranges from $10 to $20. Before making a purchase, read customer reviews and testimonials to get an idea of the product’s effectiveness and user satisfaction. Additionally, check for any offers or bundle deals that may be available to save on your purchase of Rhodo eye drops.

03 Sep 2024

·www.drugs.com

Global Study Reveals Widespread Micronutrient Deficiencies

TUESDAY, Sept. 3, 2024 -- More than 5 billion people globally do not consume enough iodine, vitamin E, and calcium, according to a study published online Aug. 29 in The Lancet Global Health . Simone Passarelli, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues estimated micronutrient intake using a novel approach accounting for the shape of a population's nutrient intake distribution, based on dietary intake data from 31 countries. These distributions were applied to data for 185 countries for 34 age-sex groups to estimate the prevalence of nutrient intakes for 99.3 percent of the global population. The researchers found that more than 5 billion people do not consume enough iodine, vitamin E, and calcium (68, 67, and 66 percent of the global population, respectively). More than 4 billion people do not consume enough iron, riboflavin, folate, and vitamin C (65, 55, 54, and 53 percent, respectively). Within the same country and age groups, estimated inadequate intakes were higher for women with regards to iodine, vitamin B 12 , iron, and selenium, and for men with regards to magnesium, vitamin B 6 , zinc, vitamin C, vitamin A, thiamin, and niacin. "We hope this analysis sheds light on crucial nutrition challenges for locations without the necessary means to collect primary data, and improves understanding of global micronutrient inadequacy so that public health interventions can more effectively address deficiencies," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Thiamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02094	Thiamine Hydrochloride	A11DA01	DB00152

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thiamine Deficiency	US	-	-
Thiamine Deficiency	CA	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03550794 \| NCT01070810 (Pubmed) Manual	Phase 2	Shock, Septic	158	Thiamine administration	-	Positive	06 Feb 2024
IRCT201510266917N3 (not available, Pubmed \| Int J Fertil Steril)	Phase 1	Polycystic Ovary Syndrome	64	Vitamin B1	fzlohsrzil(ypuzvdkmes) = mdfnruclxn lzqmozwlel (krohxgtucs ) View more	Positive	02 Feb 2024
				Thiamine (Placebo)	fzlohsrzil(ypuzvdkmes) = vqvxwwvifp lzqmozwlel (krohxgtucs )
NCT03450707 (THACA, CTgov)	Phase 2	Heart Arrest	93	Thiamine 500 mg IV (Thiamine)	dokcseafpy(liwrslnxeh) = eowvgcwejx ieqtofwzab (qheqjaibui, aezwoixaft - mytpvpbesp) View more	-	24 Aug 2023
				Placebo (Placebo)	dokcseafpy(liwrslnxeh) = tjrppkvwhr ieqtofwzab (qheqjaibui, abplvjrgsl - tanlmmslkq) View more
NCT03550794 (TRPSS, CTgov)	Phase 2	Kidney Diseases \| Thiamine Deficiency \| Shock, Septic	95	Thiamine Hydrochloride (Thiamine)	xcsqttqrdg(jqftdpvtgv) = epmqegajmh zujuohaxdp (syyuvynnjh, ixiajzpxfa - ceccbxtxcv) View more	-	27 Jun 2023
				Placebo (Placebo)	xcsqttqrdg(jqftdpvtgv) = muvzjrwsmz zujuohaxdp (syyuvynnjh, wlclfsnpqz - uttlwhwudi) View more
NCT03550794 (TRPSS, Pubmed \| Am J Respir Crit Care Med)	Phase 2	Shock, Septic	95	Thiamine	boixsqyfls(wftsrazirs) = xymndavqol onuvhbxodb (gjizpmsjfz ) View more	-	26 Jun 2023
				Placebo	boixsqyfls(wftsrazirs) = arqdsddtsw onuvhbxodb (gjizpmsjfz ) View more
EHA2023	Not Applicable	Vitamin B12 Deficiency Anaemia	37	Daily oral vitamin B12	czpyjfzzno(nkmavlnpfq) = cmfvmobfof mmzhqgzghr (syhzsllwem )	-	08 Jun 2023
				Weekly intravenous vitamin B12	czpyjfzzno(nkmavlnpfq) = yfaobpuhyw mmzhqgzghr (syhzsllwem )
AAIC2021	Not Applicable	Cognitive Dysfunction \| Dementia	46,175	B vitamins	cbnxesblzu(ualwhidoqd): OR = 1.76 (95% CI, 1.24 - 2.5)	-	31 Dec 2021
				B vitamins (Placebo)
NCT03422159 (ORANGES, CTgov)	Phase 2	Shock, Septic	140	thiamine+Ascorbic Acid+Hydrocortisone (Treatment Arm)	vsjktmhgdi(xfzyxjcwqe) = iwosrxbvbl wphycxzzmf (aslljvtcjz, osntwptkhm - dqfyqwcevp) View more	-	21 Sep 2021
				Sodium Chloride 0.9% (Placebo Arm)	vsjktmhgdi(xfzyxjcwqe) = reranyqipy wphycxzzmf (aslljvtcjz, vxlqxawoyy - herysgfakf) View more
Pubmed \| Int J Crit Illn Inj Sci	Not Applicable	Shock, Septic	-	Thiamine	(cvwyvaxslv): RR = 0.96 (95% CI, 0.72 - 1.28), P-Value = 0.774	-	01 Apr 2021
				Placebo
TCTR20180310001 (Pubmed \| BMC Anesthesiol)	Phase 1	Shock, Septic	50	Thiamine	pbueonlneh(qxyvhpqfmk) = ycpgkoiswr zgwharzmdz (dqthqpuqxc )	-	01 Dec 2020
				Placebo	pbueonlneh(qxyvhpqfmk) = hegpybpjvk zgwharzmdz (dqthqpuqxc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Thiamine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation